Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)

Yukari Tsubata; Kana Watanabe; Ryota Saito; Atsushi Nakamura; Hiroshige Yoshioka; Mami Morita; Ryoichi Honda; Nobuhiro Kanaji; Satoshi Oizumi; Daisuke Jingu; Taku Nakagawa; Kensuke Nakazawa; Atsuto Mouri; Susumu Takeuchi; Naoki Furuya; Yuki Akazawa; Kiyotaka Miura; Eiki Ichihara; Makoto Maemondo; Satoshi Morita; Kunihiko Kobayashi; Takeshi Isobe

doi:10.1007/s10147-022-02118-8

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)

Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Oizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi MoritaKunihiko Kobayashi, Takeshi Isobe

University Hospital

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

Original language	English
Pages (from-to)	823-824
Number of pages	2
Journal	International Journal of Clinical Oncology
Volume	27
Issue number	4
DOIs	https://doi.org/10.1007/s10147-022-02118-8
Publication status	Published - Apr 2022

ASJC Scopus subject areas

Surgery
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10147-022-02118-8

Fingerprint

Dive into the research topics of 'Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)'. Together they form a unique fingerprint.

Cite this

Tsubata, Y., Watanabe, K., Saito, R., Nakamura, A., Yoshioka, H., Morita, M., Honda, R., Kanaji, N., Oizumi, S., Jingu, D., Nakagawa, T., Nakazawa, K., Mouri, A., Takeuchi, S., Furuya, N., Akazawa, Y., Miura, K., Ichihara, E., Maemondo, M., ... Isobe, T. (2022). Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2). International Journal of Clinical Oncology, 27(4), 823-824. https://doi.org/10.1007/s10147-022-02118-8

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2). / Tsubata, Yukari; Watanabe, Kana; Saito, Ryota et al.
In: International Journal of Clinical Oncology, Vol. 27, No. 4, 04.2022, p. 823-824.

Research output: Contribution to journal › Comment/debate › peer-review

Tsubata, Y, Watanabe, K, Saito, R, Nakamura, A, Yoshioka, H, Morita, M, Honda, R, Kanaji, N, Oizumi, S, Jingu, D, Nakagawa, T, Nakazawa, K, Mouri, A, Takeuchi, S, Furuya, N, Akazawa, Y, Miura, K, Ichihara, E, Maemondo, M, Morita, S, Kobayashi, K & Isobe, T 2022, 'Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)', International Journal of Clinical Oncology, vol. 27, no. 4, pp. 823-824. https://doi.org/10.1007/s10147-022-02118-8

Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M et al. Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2). International Journal of Clinical Oncology. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8

Tsubata, Yukari ; Watanabe, Kana ; Saito, Ryota et al. / Correction to : Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2). In: International Journal of Clinical Oncology. 2022 ; Vol. 27, No. 4. pp. 823-824.

@article{374cc63756b94a83be9b034924b90e77,

title = "Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)",

abstract = "In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.",

author = "Yukari Tsubata and Kana Watanabe and Ryota Saito and Atsushi Nakamura and Hiroshige Yoshioka and Mami Morita and Ryoichi Honda and Nobuhiro Kanaji and Satoshi Oizumi and Daisuke Jingu and Taku Nakagawa and Kensuke Nakazawa and Atsuto Mouri and Susumu Takeuchi and Naoki Furuya and Yuki Akazawa and Kiyotaka Miura and Eiki Ichihara and Makoto Maemondo and Satoshi Morita and Kunihiko Kobayashi and Takeshi Isobe",

note = "Publisher Copyright: {\textcopyright} The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2022.",

year = "2022",

month = apr,

doi = "10.1007/s10147-022-02118-8",

language = "English",

volume = "27",

pages = "823--824",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Correction to

T2 - Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)

AU - Tsubata, Yukari

AU - Watanabe, Kana

AU - Saito, Ryota

AU - Nakamura, Atsushi

AU - Yoshioka, Hiroshige

AU - Morita, Mami

AU - Honda, Ryoichi

AU - Kanaji, Nobuhiro

AU - Oizumi, Satoshi

AU - Jingu, Daisuke

AU - Nakagawa, Taku

AU - Nakazawa, Kensuke

AU - Mouri, Atsuto

AU - Takeuchi, Susumu

AU - Furuya, Naoki

AU - Akazawa, Yuki

AU - Miura, Kiyotaka

AU - Ichihara, Eiki

AU - Maemondo, Makoto

AU - Morita, Satoshi

AU - Kobayashi, Kunihiko

AU - Isobe, Takeshi

PY - 2022/4

Y1 - 2022/4

N2 - In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

AB - In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

UR - http://www.scopus.com/inward/record.url?scp=85125730913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125730913&partnerID=8YFLogxK

U2 - 10.1007/s10147-022-02118-8

DO - 10.1007/s10147-022-02118-8

M3 - Comment/debate

C2 - 35257278

AN - SCOPUS:85125730913

SN - 1341-9625

VL - 27

SP - 823

EP - 824

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 4

ER -